Apellis raises $60mm in Series E round

15:40 EDT 10 Aug 2017 | Elsevier Business Intelligence

Apellis Pharmaceuticals Inc. (immunotherapies for autoimmune and inflammatory diseases) raised $60mm through its Series E rou...

Original Article: Apellis raises $60mm in Series E round


More From BioPortfolio on "Apellis raises $60mm in Series E round"

Quick Search

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...